Osaka, Japan

Sumihiro Nomura

USPTO Granted Patents = 29 


 

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 109(Granted Patents)


Location History:

  • Omiya, JP (1989)
  • Misato, JP (1994)
  • Kasukabe, JP (1993 - 1996)
  • Saitama, JP (2006 - 2013)
  • Kawaguchi, JP (1999 - 2014)
  • Osaka, JP (2009 - 2016)

Company Filing History:


Years Active: 1989-2016

Loading Chart...
Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents

Title: The Innovative Mind of Sumihiro Nomura: A Contributor to SGLT Inhibition

Introduction: Sumihiro Nomura, an accomplished inventor based in Osaka, Japan, holds an impressive portfolio of 29 patents. His work primarily focuses on the development of compounds that serve as inhibitors for sodium-dependent glucose transporters (SGLT), contributing significantly to the fields of diabetes research and therapy.

Latest Patents: Among his notable recent inventions are two significant patents titled "Process for the preparation of compounds useful as inhibitors of SGLT-2." These patents detail a novel process for preparing compounds that exhibit inhibitory activity against SGLT-2 found in the intestine and kidney. This groundbreaking work is essential in the pursuit of effective treatments for conditions related to glucose metabolism.

Career Highlights: Sumihiro Nomura has made substantial contributions to the pharmaceutical industry through his affiliations with reputable companies. He has worked with Mitsubishi Tanabe Pharma Corporation and Tanabe Seiyaku Company, Limited, where his innovative ideas have led to significant advancements in therapeutic compounds.

Collaborations: Throughout his career, Nomura has collaborated with esteemed colleagues including Takayuki Kawaguchi and Kenji Tsujihara. These partnerships have facilitated the exchange of ideas and bolstered the development of new inventions, further enhancing the field of medical science.

Conclusion: Sumihiro Nomura's extensive patent portfolio and collaborative efforts underline his dedication to innovation in the pharmaceutical sector. His advancements in SGLT inhibitor compounds not only reflect his inventive genius but also signify a pivotal step forward in addressing critical health challenges related to glucose transport.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…